A diversified pipeline partly built on a unique drug delivery technology NanoZolid and partly based on LIDDS novel API, NOV202
LIDDS is a company built on research and development. The company has developed a unique drug delivery technology, which has been utilized in the generation of an oncology pipeline with a mix of in-house and partnered programs from early to late-stage development. The pipeline represents new treatment options for patients suffering from severe oncological conditions where the proprietary drug delivery technology is designed to improve efficacy and safety for the patients.
In addition, LIDDS owns and develops NOV202, that has shown very strong efficacy data within several different cancer cell-lines.
